



21 April 2017.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Sub: Clarification on US FDA inspection at Dadra facility

Dear Sir/Madam,

This is with reference to your email dated April 21, 2017 seeking clarification on the US FDA inspection at the Company's Dadra facility. We hereby submit our response to your queries below:

a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order.

Response – The Company's Dadra facility underwent an inspection by US FDA recently. This inspection was completed on April 13, 2017. A Form-483 observation letter was issued by the US FDA post the inspection, listing 11 observations. We are currently in the process of responding to the said letter to the US FDA within the stipulated timeline of 15 days.

b) The material impact of this article on the Company.

Response – Regarding the material impact of US FDA inspection at Dadra facility, we clarify as under:

Sun Pharma and its subsidiaries have many facilities which supply products to the US market. These facilities undergo periodic routine inspection by the US FDA in normal course of business. As indicated above, we are in the process of responding to the US FDA for the Form-483 observation letter issued for the Dadra facility. If there are any material developments related to this inspection, we will promptly inform the stock exchanges.

c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations.

Response – No.

Yours faithfully,

For Sun Pharmaceutical Industries Ltd,

Ashok I. Bhuta
Compliance Officer

CC: BSE Ltd., Mumbai.